Renal protective potential of antihypertensive drugs

Bibliography

• UNITED STATES RENAL DATA SYSTEM (USRDS): Incidence and prevalence of ESRD. Am. J. Kidney Dis. (1999) 34 (Suppl. 1):S40–S50.
   Google Scholar
• RITZ E, RYCHLIK I, LOCATELLI F, HALIMI S: End-stage renal failure in Type 2 diabetes: a medical catastrophe of worldwide dimensions. Am. J Kidney Dis. (1999) 34 (5):795–808.
   PubMed Web of Science ®Google Scholar
• SUSIC D, FROHLICH ED: Nephroprotective effect of antihypertensive drugs in essential hypertension. J Hypertens. (1999) 16 (5):555–567.
   Web of Science ®Google Scholar
• WEIR MR: Diabetes and hypertension: blood pressure control and consequences. Am. J Hypertens. (1999) 16 (Suppl.):170S–178S.
   Google Scholar
• GRIFFIN KA, PICKEN M, BIDANI AK: Radiotelemetric BP monitoring, antihypertensives and glomeruloprotec-tion in remnant kidney model. Kidney Int. (1994) 46:1010–1018.
   PubMed Web of Science ®Google Scholar
• KLAG MJ, WHELTON PK, RANDALL BL et al: Blood pressure and end-stage renal disease in men. N Engl. J. Med. (1996) 334:13–18.
   PubMed Web of Science ®Google Scholar
• BREYER LEWIS J, BERL T, BAIN RP et al: Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Am. J. Kidney Dis. (1999) 34:809–817.
   PubMed Web of Science ®Google Scholar
• THE GISEN GROUP: Randomized placebo-controlledtrial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet (1997) 349:1857–1863.
   PubMed Web of Science ®Google Scholar
• THE HEART OUTCOMES PREVENTION EVALUATION STUDY INVESTIGATORS: Effects of ramipril on cardio-vascular and micovascular outcomes in people with diabetes mellitus: results of the HOPE and MICRO-HOPE study. Lancet (2000) 355 :253–259.
   PubMedGoogle Scholar
• SUSIC D, NUNEZ E, HOSOYA K, FROHLICH ED: Coronary hemodynamics in aging spontaneously hypertensive and normotensive Wistar-Kyoto rats. J Hypertens. (1998) 16:231–237.
   PubMed Web of Science ®Google Scholar
• SUSIC D, VARAGIC J, FROHLICH ED: Pharmacologic agents on cardiovascular mass, coronary dynamics and collagen in aged spontaneously hypertensive rats. Hypertens. (1999) 17:1209–1215.
   Web of Science ®Google Scholar
• SUSIC D, FRANCISCHETTI A, ED FROHLICH: Prolonged L-arginine on cardiovascular mass and myocardial hemodynamics and collagen in aged spontaneously hypertensive and normal rats. Hypertension (1999) 33 (Part II) :451–455.
   Google Scholar
• ANDERSON S, BRENNER BM: The role of nephron mass and of intraglomerular pressure in initiation and progression of experimental hypertensive-renal disorders. In: Hypertension: Pathophysiology, Diagnosis and Management. Laragh JH, Brenner BM (Eds.), Raven Press, New York, USA (1995):1553–1568.
   Google Scholar
• MOGENSEN CE, HANSEN KW, NIELSEN S, PEDERSEN MM, REHLING M, SCHMITZ A: Monitoring diabetic nephro-pathy: glomerular filtration rate and abnormal albuminuria in diabetic renal disease-reproduci-bility, progression, and efficacy of antihypertensive intervention. Am. J. Kidney Dis. (1993) 22:174–187.
   PubMed Web of Science ®Google Scholar
• VEDEL P, OBEL J, NIELSEN FS: Glomerular hyperfiltra-tion in microalbuminuric NIDDM patients. Diabetologia (1996) 27:547–552.
   Google Scholar
• APPERLOO AJ, DE ZEEUVV D, DE JONG PE: A short-term antihypertensive treatment induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int. (1997) 51:793–797.
   PubMed Web of Science ®Google Scholar
• HANSEN HP, ROSSING P, TARNOW L, NIELSEN FS, JENSEN BR, PARVING HH: Increased glomerular filtration rate after withdrawal of long-term an tihyp er ten sive treatment in diabetic nephropathy. Kidney Int. (1995) 47:1726–1731.
   PubMed Web of Science ®Google Scholar
• RABELNIK TJ, KOOMANS HA: Endothelial function and the kidney. An emerging target for cardiovascular therapy. Drugs (1997) 53 (Suppl. 1):11–19.
   Google Scholar
• COOPER ME: Pathogenesis, prevention and treatment of diabetic nephropathy. Lancet (1998) 352:213–219.
   PubMed Web of Science ®Google Scholar
• WOLF G, ZIYADEH FN: Molecular mechanisms of diabetic renal hypertrophy. Kidney Int. (1999) 56:393–405.
   PubMed Web of Science ®Google Scholar
• KANETO H, MORRISSEY J, KLAHR S: Increased expres-sion of TGF-I31 mRNA in obstructed kidney of rats with unilateral ureteral obstruction. Kidney Int. (1993) 44 :313–321.
   PubMed Web of Science ®Google Scholar
• SHIHAB B, BENNET WM, TANNER AM, ANDOH TF: Angiotensin II blockade decreases TGF-I31 and matrix proteins in cyclosporine nephropathy. Kidney Int. (1997) 52:660–673.
   PubMed Web of Science ®Google Scholar
• ZOJA C, DONADELLI R, CORNA D et al.: The renoprotec-tive properties of angiotensin-converting enzyme inhibitors in a chronic model of membranous nephro-pathy are solely due to the inhibition of angiotensin II: Evidence based on comparative studies with a receptor antagonist. Am] KidneyDis. (1997) 29:254–264.
   PubMed Web of Science ®Google Scholar
• SHARMA K, ELTAYEB BO, MCGOVAN TA et al.: Cap topril-induced reduction of serum levels of transforming growth factor-I31 correlates with long-term nephroprotection in insulin-dependent diabetic patients. Am. J Kidney Dis. (1999) 34:818–823.
   PubMed Web of Science ®Google Scholar
• ZIYADEH FN: The extracellular matrix in diabetic nephropathy. Am. J Kidney Dis. (1993) 22:736–744.
   PubMed Web of Science ®Google Scholar
• WOLF G: link between angiotensin II and TGF-I3 in the kidney. Miner. Electrolyte Metab. (1998) 24:174–180.
   PubMedGoogle Scholar
• RUMBLE JR, COOPER ME, SOULIS T et al.: Vascular hypertrophy in experimental diabetes: role of advanced glycation end products. J Clin. Invest. (1997) 99:1016–1027.
   PubMed Web of Science ®Google Scholar
• GILBERT RE, COX A, WU LL et al.: Expression oftransforming growth factor-I31 and Type IVcollagen in the renal tubulointerstitium in experimental diabetes: effects of angiotensin converting enzyme inhibition. Diabetes (1998) 47:414–422.
   PubMed Web of Science ®Google Scholar
• REMUZZI G, RUGENENTI P, BENIGNI A: Understandingthe nature of renal disease progression. Kidney Int. (1997) 51:2–15.
   PubMed Web of Science ®Google Scholar
• BIANCHI S, BIGGAZI R, CAMPESE VM: Microalbuminuria in essential hypertension: significance, p athophysi-ology, and therapeutic implications. Am. J Kidney Dis. (1999) 34:973–995.
   PubMed Web of Science ®Google Scholar
• REMUZZI G, BERTANI T: Pathophysiology of progres-sive nephropathies. N. Engl. J. Med. (1998) 339:1448–1456.
   PubMed Web of Science ®Google Scholar
• VIBERTI GC, THOMAS S: Should we screen for microal-buminuria in essential hypertension. Am. J Kidney Dis. (1999) 34:1139–1141.
   PubMedGoogle Scholar
• REMUZZI A, FASSI A, BERTANI T, PERICO N, REMUZZI G: ACE inhibition induces regression of proteinuria and halts progression of renal damage in genetic model of progressive nephropathy. Am. J. Kidney Dis. (1999) 34 :626–632.
   PubMed Web of Science ®Google Scholar
• MACCONI D, GHILARDI M, BONASSI ME et al.: Effect ofACE inhibition on glomerular basement membrane permeability and distribution of ZO-1 in MWF rats. J Am. Soc. Nephrol (2000) 11:477–489.
   PubMed Web of Science ®Google Scholar
• KUMAR KV, SHIFOW AA, NAIDU MU, RATNAKAR KS: Carvedilol: a beta blocker with antioxidant property protects against gentamicin-induced nephrotoxicity in rats. Life Sci. (2000) 66:2603–2611.
   PubMed Web of Science ®Google Scholar
• VAN DEN BRANDEN C, GABRIELS M, VEMECQ J, VANDENHOUTE K, VERBEELEN D: Carvedilol protects against glomerulosclerosis in the rat remnant kidney model without general changes in antioxidant enzyme status. A comparative study of two beta-blocking drugs, carvedilol and propranolol. Nephron (1997) 77:319–324.
   Google Scholar
• TARIF N, BAKRIS G: Preservation of renal function; thespectrum of effects of calcium channel blockers. Nephrol. Dial. Transplant. (1997) 12:2244–2250.
   PubMed Web of Science ®Google Scholar
• GRIFFIN KA, PICKEN MM, BIDANI AK: Deleterious effectsof calcium channel blockade on pressure transmis-sion and glomerular injury in rat remnant kidney. J Clin. Invest. (1995) 96:793–800.
   PubMed Web of Science ®Google Scholar
• BAKRIS GL, SMITH AC: Effects of sodium intake onalbumin excretion in patients with diabetic nephro-pathy treated with long-acting calcium antagonists. Ann. Intern. Med. (1996) 125:201–203.
   PubMed Web of Science ®Google Scholar
• DWORKIN LD, BENSTEIN JA, PARKER M, TOLBERT E, FEINER HD: Calcium antagonists and converting enzyme inhibitors reduce renal injury by different mechanisms. Kidney Int. (1993) 43:808–814.
   PubMed Web of Science ®Google Scholar
• FRANCISCHETTI A, ONO H, FROHLICH ED: Renoprotec-tive effect of felodipine and/or enalapril in spontane-ously hypertensive rats with and without L-NAME Hypertension (1998) 31:795–801.
   Google Scholar
• HEMMELDER MH, DE ZEEUW D, DE JONG PE: Antiprote-inuric efficacy of verapamil in comparison with to trandolapril in non-diabetic renal disease. Nephrol. Dial. Transplant. (1999) 14:98–104.
   PubMed Web of Science ®Google Scholar
• HEBERT LA, KUSEK JA, GREEN T et al.: Effects of bloodpressure control on progressive renal disease in blacks and whites. Hypertension (1997) 30:428–435.
   PubMed Web of Science ®Google Scholar
• ROSSING P, TARNOW L, BOELSKIFTE S et al.: Differencesbetween nisoldipine and lisinopril in GFRs and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment. Diabetes (1997) 46:481–487.
   PubMed Web of Science ®Google Scholar
• CAMPISTOL JM, INIGO P, JIMENEZ W et al.: IDsartan decreases plasma levels of TGF-I31 in transplant patients with chronic allograft nephropathy. Kidney Int. (1999) 56:714–719.
   PubMed Web of Science ®Google Scholar
• HOLLENBERG NK, FISHER NDL, PRICE DA: Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension (1998) 32:387–392.
   PubMed Web of Science ®Google Scholar
• WEBER M: Emerging treatments for hypertension:potential role for vasopeptidase inhibition. Am. J Hypertension (1999) 12:139S–1475.
   Google Scholar
• BENIGNI A, COLOSIO V, BRENA C, BRUZZI I, RERTANI T,REMUZZI G: Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes. Diabetes (1998) 47:450–456.
   PubMed Web of Science ®Google Scholar
• BROCHU E, LACASSE S, MOREAU C et al.: EndothelinET(A) receptor blockade prevents the progression of renal failure and hypertension in uraemic rats. Nephrol. Dial. Transplant. (1999) 14:1881–1888.
   PubMed Web of Science ®Google Scholar
• WOLF SC, BREHM BR, GASCHLER F et al.: Protective effects of endothelin antagonists in chronic renal failure. Nephrol. Dial. Transplant. (1999) 14 (Suppl. 4)29–30.
   Google Scholar
• GOMEZ-GARRE D, LARGO R, LIU XH et al.: An orally active ETA/EIB receptor antagonist ameliorates proteinuria and glomerular lesions in rats with proliferative nephritis. Kidney Int. (1996) 50:962–972.
   PubMed Web of Science ®Google Scholar
• BAKRIS GL, WEIR MR, DEQUATRO V, MCMAHON FG: Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int. (1998) 54:1283–1289.
   PubMed Web of Science ®Google Scholar
• MCLAUGHLIN K, JARDINE AG: Angiotensin converting enzyme inhibitors and angiotensin receptor (AT!) antagonists: either or both for primary renal disease. Nephrol. Dial. Transplant. (1999) 14:25–28.
   PubMed Web of Science ®Google Scholar
• RUSSO D, PISSANI A, BALLETTA MM et al.: Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am. J Kidney Dis. (1999) 33:851–856.
   PubMed Web of Science ®Google Scholar
• RUILOPE LM, ALDIGIER JC, PONTICELLI C, ODDOU-STOCK P, BOTTERI F, MANN JF: Safety of the combina-tion of valsartan and benazepril in patients with chronic renal disease. J Hypertens. (2000) 18:89–95.
   PubMed Web of Science ®Google Scholar
• BENIGNI A, CORNA D, MAFFI R, BENEDETTI G, ZOJA C, REMUZZI G: Renoprotective effect of contemporary blocking of angiotensin II and endothelin-1 in rats with membranous nephropathy. Kidney Int. (1998) 54:353–359.
   PubMed Web of Science ®Google Scholar
• MUNTER K, HERGENRODER S, KIRCHENGAST M: Endothelin-A receptor antagonist combined with hydralazine improves survival and renal function in hypertensive rats. J. Cardiovasc. Pharmacol. (1998) 31 (Suppl. 1):245–248.
   Google Scholar
• YOUSSEF S, NGUYEN DT, SOULIS T, PANAGIOTOPOU-LOS S, JERUMS G, COOPER ME: Effect of diabetes and aminog-uanidine therapy on renal advanced glycation end-product binding. Kidney Int. (1999) 55:907–916.
   PubMed Web of Science ®Google Scholar
• WOLLFENBUTTELL BH: Breakers of advanced glycationend products restore large artery properties in experi-mental diabetes. Proc. Natl. Acad. Sci. USA (1988) 95:4630-4635. Dinko Susic
   Google Scholar